Novo Nordisk to launch new drugs in blood and growth disorders after success in diabetes

Novo Nordisk, a top pharmaceutical company, is offering a lower price for its weight-loss drug Wegovy and is expanding into cardiometabolic and rare diseases. The CEO praised their semaglutide drug for its effectiveness in treating diabetes, obesity, and comorbidities like heart and kidney disease. The company is also launching new medicines for hemophilia patients.